Skip to main content
Heidelberg Pharma AG logo

Heidelberg Pharma AG — Investor Relations & Filings

Ticker · HPHA ISIN · DE000A11QVV0 LEI · 391200E09XYBYITR1W32 F Manufacturing
Open in API
Filings indexed 806 across all filing types
Latest filing 2024-03-06 Legal Proceedings Report
Country DE Germany
Listing F HPHA

About Heidelberg Pharma AG

https://heidelberg-pharma.com/en/

Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.

Recent filings

Filing Released Lang Actions
Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
Legal Proceedings Report Classification · 99% confidence The document is a press release disseminated via EQS-News, dated March 6, 2024. The content announces that Heidelberg Pharma AG will present data (efficacy data on HDP-101 and preclinical data on their ADC platform) at the upcoming American Association for Cancer Research (AACR) Meeting in April 2024. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing detailing financial results (like ER or MRQ). It is an announcement about participation in a scientific conference and the data to be presented. This type of announcement, which details corporate activities, scientific updates, and upcoming presentations, most closely aligns with a general Regulatory Filing or News Release that doesn't fit a more specific financial category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate news announcement about scientific presentations, especially since it is distributed through a news service (EQS-News). It is not a Call Transcript (CT), Investor Presentation (IP), or Earnings Release (ER).
2024-03-06 English
Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
Capital/Financing Update Classification · 98% confidence The document is a press release dated March 4, 2024, announcing a 'Royalty Financing Agreement' for up to USD 115 million. This transaction involves the sale of future royalties related to a diagnostic agent (Zircaix TM). The core subject is a significant financing/fundraising activity for the company. This aligns directly with the definition of 'Capital/Financing Update' (Code: CAP). Although it mentions a conference call related to the Annual Report, the primary content is the financing deal itself, not the report or the voting results.
2024-03-04 English
Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
Capital/Financing Update Classification · 99% confidence The document is an 'Ad-hoc announcement' disclosing 'inside information' regarding a 'Royalty Financing Agreement' for up to USD 115 million. This concerns a significant financial transaction, specifically related to future royalties from a drug asset. This type of announcement, detailing fundraising or financing activities, aligns best with the 'Capital/Financing Update' category. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific corporate finance event. The document length is substantial (8019 chars), so it is not a simple RPA.
2024-03-04 English
Heidelberg Pharma AG: Walter Miller, Annahme der Gewahrung von 60.000 Aktienoptionen im Rahmen des Aktienoptionsprogramms 2023 fur Mitarbeiter und Vorstandsmitglieder der Heidelberg Pharma AG. ...
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains structured information detailing a transaction by a member of the board ('Vorstand'), Walter Miller. Section 2 states 'Grund der Meldung' (Reason for Notification) and Section 4 details the transaction, which involves the acceptance of stock options as part of an employee program. This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). The corresponding code is DIRS.
2024-01-31 German
Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, Annahme der Gewahrung von 60.000 Aktienoptionen im Rahmen des Aktienoptionsprogramms 2023 fur Mitarbeiter und Vorstandsmitglieder der Heidelberg ...
Director's Dealing Classification · 100% confidence The document explicitly uses the header 'Directors’ Dealings' and details a transaction ('Annahme der Gewährung von 60.000 Aktienoptionen') by a member of the management board ('Vorstand'), Prof. Dr. Andreas Pahl. This directly corresponds to the definition of Director's Dealing (insider trades by executives). The filing type code for this is DIRS.
2024-01-31 German
Heidelberg Pharma AG: Dr. Jan Schmidt-Brand, Annahme der Gewahrung von 60.000 Aktienoptionen im Rahmen des Aktienoptionsprogramms 2023 fur Mitarbeiter und Vorstandsmitglieder der Heidelberg ...
Director's Dealing Classification · 100% confidence The document title explicitly states 'Directors’ Dealings' and the content details a transaction ('Annahme der Gewährung von 60.000 Aktienoptionen') by a member of the management board ('Vorstand'), Dr. Jan Schmidt-Brand. This directly corresponds to the definition of Director's Dealing, which is classified as 'DIRS'. The date of the transaction (2023-07-19) is noted, and the announcement date is 31 January 2024.
2024-01-31 German

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.